Who we are?
PlexBio Co., Ltd. (6572), established in December 2009, is a leading Taiwanese in vitro diagnostic reagent developer and manufacturer with its self-developed Precision Image Code MicroDisc (πCode®), advanced patented technology, and IntelliPlex™ testing system.
Innovative Detection Solutions for Quality Health Care
PlexBio’s groundbreaking core detection technology, the Precision Image Code MicroDisc, enables the simultaneous detection of dozens to hundreds of biomarkers from a single specimen. The platform focuses particularly on cancer-related applications, offering assay solutions that cover hundreds of genetic mutation sites.
The system supports high-throughput analysis across a large number of samples. PlexBio remains committed to advancing molecular detection technologies and delivering cutting-edge in vitro diagnostic solutions to support better health outcomes worldwide.
The system supports high-throughput analysis across a large number of samples. PlexBio remains committed to advancing molecular detection technologies and delivering cutting-edge in vitro diagnostic solutions to support better health outcomes worldwide.
Meeting International Standards for Product Excellent！
We adhere to international standards throughout all stages, including CE-IVDR compliance, from research through manufacturing. Backed by certifications like TFDA GMP/QMS and ISO13485, we guarantee the highest levels of product excellence and safety for your satisfaction.
-
Precise
Leveraging our core competencies to acquire the ability to accurately determine mutations, we meet customer needs precisely -
Speedy
The capability to expand instantly responds quickly to market needs -
Simple and Convenient
Ease-of-use platform has been developed to streamline the process of experimental operation and improve the performance of experimental operations. -
Economic
The affordable cost raises our competitiveness in the market.
Plexbio Focused On Providing More Accurate, Convenient And Cost-competitive Products
PlexBio is dedicated to the development of innovative, high-performance, and diversified in vitro diagnostic reagents for molecular biology and immunology projects. For the past three consecutive years, we have been honored as one of the top 500 tech companies in the Asia-Pacific region, making us a leading brand and significant player in the global in vitro assay market.
-
Precise
Leveraging our core competencies to acquire the ability to accurately determine mutations, we meet customer needs precisely -
Speedy
The capability to expand instantly responds quickly to market needs -
Simple and Convenient
Ease-of-use platform has been developed to streamline the process of experimental operation and improve the performance of experimental operations. -
Economic
The affordable cost raises our competitiveness in the market.
